Diffuse Large B Cell Lymphoma Archives

Axi-cel improved event-free survival in R/R DLBCL

Presented By

Dr Frederick Locke, Moffitt Cancer Cancer, FL, USA

Trial

Phase 3, ZUMA-7

Conference

ASH 2021

4 February, 2022 11:09

Novel anti-CD19 plus lenalidomide prolonged survival in R/R DLBCL

Expert

Dr Grzegorz Nowakowski, Mayo Clinic, Rochester, USA

Trial

Cohort study, RE-MIND2

Conference

ASH 2021

4 February, 2022 11:08

Axi-cel more effective but tisa-cel less toxic in DLBCL

Presented By

Dr Emmanuel Bachy, Hospices Civils de Lyon, France

Conference

ASH 2021

4 February, 2022 11:01

POLARIX: Novel regimen superior to R-CHOP in DLBCL

Presented By

Prof. Hervé Tilly, University of Rouen, France

Trial

Phase 3, POLARIX

Conference

ASH 2021

4 February, 2022 10:56

CIRS is predictive of outcomes in CAR T-cell recipients with R/R DLBCL

Expert

Dr Geoffrey Shouse, City of Hope Comprehensive Cancer Center, USA

Conference

ASH 2021

4 February, 2022 10:20

Comparable outcomes with second-line tisa-cel versus standard-of-care for relapsed/refractory aggressive NHL

Expert

Dr Michael R. Bishop, David and Etta Jonas Center for Cellular Therapy, University of Chicago, USA

Trial

Phase 3, BELINDA

Conference

ASH 2021

4 February, 2022 10:03

Mutational analyses are predictive in malignant lymphomas

Presented By

Dr Ismael Fernández-Miranda, Institute of Sanitary Investigation Puerta de Hierro, Spain & Dr Shan-Shan Li, Hospital of Sun Yat-sen University, China

Conference

ESMO 2021

19 November, 2021 09:19

Escalating the ESCALADE trial: untreated diffuse large B-cell lymphoma

Presented By

Dr Laurie Sehn, University of British Columbia, Vancouver, Canada

Trial

Phase 3, ESCALADE

Journal

Physician's Weekly

Conference

ASCO 2021

6 August, 2021 12:36

Naratuximab emtansine + rituximab safe and effective in diffuse large B-cell lymphoma

Presented By

Dr Moshe Yair Levy, Texas Oncology-Baylor Charles A. Sammons Cancer Center, USA

Conference

EHA 2021

5 August, 2021 11:55

Promising chemo-free treatment options in r/r DLBCL

Presented By

Prof. Marco Ladetto, University del Piemonte Orientale, Italy

Trial

LOTIS-2

Conference

EHA 2021

5 August, 2021 11:17

Infectious complications mild and not common in patients receiving CAR-T therapy for diffuse large B cell lymphoma

Presented By

Dr Roberta Di Blasi, Hospital Saint-Louis, France

Trial

JULIET and ZUMA1

Conference

EHA 2019

9 August, 2019 19:55

Obinutuzumab/polatuzumab in follicular lymphoma

Presented By

Prof. Wojciech Jurczak, Jagiellonian University, Poland

Conference

EHA 2019

9 August, 2019 17:13

Medical Conferences

Tag: Diffuse Large B Cell Lymphoma

Axi-cel improved event-free survival in R/R DLBCL

Novel anti-CD19 plus lenalidomide prolonged survival in R/R DLBCL

Axi-cel more effective but tisa-cel less toxic in DLBCL

POLARIX: Novel regimen superior to R-CHOP in DLBCL

CIRS is predictive of outcomes in CAR T-cell recipients with R/R DLBCL

Comparable outcomes with second-line tisa-cel versus standard-of-care for relapsed/refractory aggressive NHL

Mutational analyses are predictive in malignant lymphomas

Escalating the ESCALADE trial: untreated diffuse large B-cell lymphoma

Naratuximab emtansine + rituximab safe and effective in diffuse large B-cell lymphoma

Promising chemo-free treatment options in r/r DLBCL

Infectious complications mild and not common in patients receiving CAR-T therapy for diffuse large B cell lymphoma

Obinutuzumab/polatuzumab in follicular lymphoma